Search

Objective: to assess how cerebral stroke (CS) in patient’s history affectы length life of patients with stable coronary heart disease (СHD), included in the СHD PROGNOSIS registry.Materials and methods. We analyzed the data of patients from CHD PROGNOSIS registry who underwent coronary angiography and confirmed CHD diagnosis (n = 541, including 432 men and 109 women) during the reference hospitalization in the National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of Russia from 01 / 01 / 2004 to 31 / 12 / 2007. The average age of men and women was 57.5 ± 0.4 and 60.9 ± 0.9 years, respectively. During reference hospitalization, we took into account CS / transient ischemic attack in anamnesis (retrospective part) and frequency of reaching endpoints (general and cardiovascular mortality, myocardial infarction and CS after 4 and 7 years of follow-up (prospective part). In case of 4-year observation, therapy response was 89 %, in case of 7-year observation – 93 %.Results. Twenty (3.7 %) patients had CS or transient ischemic attack in anamnesis at reference hospitalization, 284 (52.5 %) patients suffered myocardial infarction (p < 0.001). There were revealed differences in patients with coronary artery disease, which cannot be detected in the anamnesis by age, sex, presence of comorbid burden, arterial hypertension and diabetes mellitus, non-cardiological diseases, smoking frequency. The relative risk of death from all causes at 4- and 7-year follow-up was 3.3 and 2.4 times higher, respectively (p < 0.05). Patients with CS in anamnesis demonstrated 25 and 45 % overall mortality in 4 and 7 years, their cardiovascular mortality was 25 and 35 %, respectively. Patients without CS in medical history demonstrated 9 and 18 % overall mortality after 4 and 7 years of follow-up, cardiovascular mortality was 8 and 12 %, respectively (intergroup differences are statistically significant at p < 0.05–0.01).Conclusion. It was noted that patients with CHD and CS in anamnesis were older, percent of women among them was higher, they more often suffered from grade II–III hypertension and diabetes mellitus, had more comorbidities, but smoked less often. CS in anamnesis significantly worsened the medium-term and long-term life prognosis for patients with CHD, increasing overall and cardiovascular mortality.

In the review article are provided the approaches to the therapy for improvement of prognosis in patients with peripheral and multifocal atherosclerosis which are available now; some limitations and a real situation are designated for the antithrombotic therapy in this category of patients. According to the clinical trial COMPASS the prospects of wide use of a combination of acetylsalicylic acid and a rivaroxsaban of 2.5 mg 2 times a day in the patients with chronic coronary heart disease and/or symptom peripheral atherosclerosis are designated.Нуждаются ли пациенты с атеросклерозом периферических артерий в медикаментозной терапии до проведения реваскуляризации? В обзорной статье представлены имеющиеся в настоящее время подходы к назначению терапии, улучшающей прогноз у пациентов с периферическим и мультифокальным атеросклерозом, обозначены ограничения и реальная ситуация с назначением антитромботической терапии у этой категории пациентов. На основании данных исследования COMPASS обозначены перспективы широкого использования комбинации ацетилсалициловой кислоты и ривароксабана 2,5 мг 2 раза в день у пациентов с хронической ишемической болезнью сердца и/или симптомным периферическим атеросклерозом.

Анализ индекса массы тела (ИМТ) в группах госпитальных больных ишемической болезнью сердца (ИБС) 60 лет и старше выявил этнические, гендерные, возрастные различия. Существенно более высокие значения ИМТ, соответствующие ожирению (p, An analysis of the body mass index (BMI) revealed the ethnic, gender, age differences among the groups of hospital patients with coronary heart disease (CHD) aged over 60. Significantly higher value of BMI was identified in non-indigenous patients compared to Yakut group that was respective to the obesity of p, №4(64) (2019)

Patients with advanced chronic kidney disease (CKD), including those treated with dialysis, are at high risk for the development of cardiovascular disease (CVD). CVD accounts for 45-50% of deaths among dialysis patients. Therapy of acute and chronic coronary heart disease (CHD) that is effective in the general population is frequently less effective in patients with advanced CKD. Drug therapy in such patients may require dose modification in some cases. Oral anti-platelet drugs are less effective in those with advanced CKD than in persons with normal or near normal renal function. The intravenous antiplatelet drugs eptifibatide and tirofiban both require dose reductions in patients with advanced CKD. Enoxaparin requires dose reduction in early stage CKD and is contraindicated in hemodialysis patients. Unfractionated heparin and warfarin maybe used without dose adjustment in CKD patients. Atenolol, acetbutolol and nadolol may require dose adjustments in CKD. Metoprolol and carvedilol do not. Calcium channel blockers and nitrates do not require dose adjustment, whereas ranolazine does. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers may safely be used in CKD patients with close observation for hyperkalemia. The safety of spironolactone in such patients is questionable. Statins are less effective in reducing cardiovascular complication in CKD patients and their initiation is not recommended in dialysis patients. Coronary artery bypass grafting is associated with higher short-term mortality, but better long-term morbidity and mortality than percutaneous coronary interventions in patients with advanced CKD with non-ST segment ACS and chronic CHD.

Aim. To study the prevalence of selected parameters of subclinical atherosclerosis and their association with muscle function and muscle volume in patients with different levels of cardiovascular risk (CVR). Material and methods. The study included 20 patients (11 men and 9 women; mean age 54,5±8,5 years) with chronic coronary heart disease (CCHD; mean duration 6,4±2,3 years) in the main group (MG), as well as 20 CCHD-free people in the control group (CG). Arterial stiffness was assessed by pulse wave velocity (PWV) and calculated carotid-femoral index (CFI). Endothelial function was assessed by endothelium-dependent vasodilatation (EDVD) in the reactive hyperemia (RH) test. Common carotid artery (CCA) ultrasound was performed in order to assess intima-media thickness (IMT) of carotid arteries. All participants underwent veloergometry (VEM); exercise capacity (EC) was measured by calculated metabolic equivalents (MET). Muscle tissue volume was assessed using a bioelectrical impedance analyser. The percentage of active muscle mass (%AMM) and fat-free muscle mass (%FFM), out of the total body mass, was calculated. Results. Increased CFI values >12 m/s, as a marker of adverse prognosis, were observed in 20% CCHD patients and in 10% of controls (z=0,17; p=0,87). Vasomotor endothelial dysfunction (EDVD 0,9 mm were observed in 55% and 15%, respectively (z=2,3; p=0,02). Most patients with pathologically increased arterial stiffness and vasomotor endothelial dysfunction had low EC. In CCHD patients with low EC, CFI significantly correlated with %AMM and %FFM (r=-0,32; pConclusion. EDVD and PWV reflect the lower PA levels and functional disadaptation of CCHD patients, which can result in a faster progression of atherosclerosis.

OBJECTIVES The aim of the present study was to evaluate the expression and the activity of vascular endothelial growth factor (VEGF) in the hearts of diabetic patients with chronic coronary heart disease (CHD). BACKGROUND Diabetes is characterized by a decreased collateral vessel formation in response to coronary ischemic events, although the role of VEGF in human diabetic macroangiopathy has not been fully investigated. METHODS Biopsies of left ventricular (LV) myocardium were obtained from 10 patients with type 2 diabetes and 10 non-diabetic patients with chronic CHD, all undergoing surgical coronary revascularization. Right ventricle myocardial samples taken from normal hearts were used as control specimens. Vascular endothelial growth factor and VEGF-receptors (flt-1 and flk-1) were evaluated by Western blot, reverse transcriptase-polymerase chain reaction (RT-PCR) and real-time RT-PCR. Akt and endothelial nitric oxide synthase (eNOS) protein expression and their phosphorylated forms were also evaluated by Western blot. RESULTS Vascular endothelial growth factor, flt-1, and flk-1 messenger ribonucleic acid (mRNA) and protein expressions were increased in non-diabetic patients with CHD compared with control subjects. Remarkably, in diabetic patients, VEGF mRNA and protein levels were significantly higher, whereas flt-1, flk-1 mRNA, and protein were lower when compared with nondiabetic patients. Interestingly, phospho–flk-1 was reduced in diabetic patients compared with non-diabetic patients. As a consequence, Akt phosphorylation, eNOS protein and its phosphorylated form were significantly higher in the samples from non-diabetic patients compared with diabetic patients. CONCLUSIONS Chronic CHD in diabetic patients is characterized by an increased VEGF myocardial expression and a decreased expression of its receptors along with a down-regulation of its signal transduction. The latter could be partially responsible for the reduced neoangiogenesis in diabetic patients with ischemic cardiomyopathy

BackgroundSeveral biohumoral variables, taken individually, are predictors of prognosis in patients with chronic coronary artery disease (CAD). We hypothesized that taken together, laboratory tests provide prognostic information that is additive to a complete diagnostic work-up.MethodsWe prospectively examined 2370 consecutive patients with chronic CAD, as shown by a >50% coronary stenosis (in 95% of patients), previous coronary revascularization (in 31% of patients), and/or previous myocardial infarction (MI, in 54% of patients). We tested the ability of laboratory and clinical variables to predict future cardiac events (cardiac death and non-fatal MI).ResultsDuring follow-up (median, 46 months), 147 patients (6.2%) died from cardiac causes and 81 (3.4%) experienced a non-fatal MI. Using multivariate analysis, after adjustment for clinical variables (including left ventricular ejection fraction and angiographic extent of coronary stenoses), a high-density lipoprotein cholesterol (HDLc) concentration2.4 (p=0.0014), and an fT3 serum level

Aim.To assess effectiveness and safety of a new rehabilitation method — interval hypoxia-hyperoxia training (IHHT) — in patients with chronic coronary heart disease (CCHD).Material and methods.This pilot study included 40 CCHD patients, Functional Class II–III (31 men and 9 women; mean age 61,7±7,7 years). The IHHT group (n=30) underwent 20 procedures (duration 40–50 minutes, 5 times a week), while the control group (n=10) underwent 20 similar placebo procedures. The REOXY device (AIMediqS.A., Luxemburg) was used for the creation of the gas mixtures with O2 content from 10% to 35–40%. At baseline and in the end of the treatment, individual hypoxia sensitivity was assessed in a 10-minute hypoxic test (HT). The IHHT procedure started with 5–7 minutes of mask inhalation of 12–11% О2, followed by 2–3 minutes of mask inhalation of 30% O2. The automatic switch between the gas mixtures followed the biological feedback principle; one procedure included 6–8 hypoxiahyperoxia cycles. Before and after the intervention phase, all participants underwent clinical and biochemical blood assay, rest ECG, submaximal treadmill test (time of the test, workload, and exercise capacity in metabolic equivalent units (MET)).Results.After the IHHT course, the main group demonstrated a significant increase in exercise capacity: test time increased by 34,1% (vs. —2,7% in controls), while exercise capacity (MET) increased by 15,8% (vs. 5,4% in controls), and the prevalence of angina attacks as the result of test termination significantly decreased. Improved exercise capacity was associated with a significant reduction in total cholesterol, plasma triglycerides, initially elevated blood pressure and resting heart rate, as well as with an elevated hypoxia tolerance threshold in the HT. In all participants, IHHT was well tolerated and free from adverse effects.Conclusion.The IHHT method increases exercise capacity in CCHDpatients, which is associated with lipid profile normalisation, blood pressure reduction, decreased number of angina attacks, and increased resistance to hypoxia.

Aim. To identify the value of selected parameters and integral indices of treadmill test (TT), such as Duke Treadmill Score (DTS), Centre for Preventive Medicine index (CPMI), and modified CPMI, in the assessment of cardiovascular complication (CVC) risk among patients with chronic coronary heart disease (CCHD). Material and methods. The study included all consecutive patients with the admission diagnosis of CCHD (n=260), who underwent coronary angiography (CAG) and TT in the period from January 1st 2004 to December 31st 2007, and were permanent residents of Moscow City or Moscow Region. Primary end-point was death from all causes; non-fatal CVC included acute myocardial infarction, acute cerebrovascular accident, and revascularization (percutaneous coronary intervention or coronary artery bypass graft surgery). Results. The mean time to the development of primary end-point was 3,2 years; it total, it was registered in 71 patients (32,0 %). The incidence of primary end-point was higher in patients with ST segment depression ≥1 mm at TT, positive TT result, or chest pain development during the test. Achievement of target heart rate and TT time ≥12 minutes was associated with a better prognosis. In patients with high and intermediate risk by DTS and CPMI, the incidence of primary end-point was higher than in patients with low risk. Modified CPMI demonstrated high correlation with the primary end-point. Conclusion. The highest prognostic value in the assessment of the risk of CCHD complications was demonstrated by TT result, ST segment depression ≥1 mm, TT time, and chronotropic TT response. The role of CPMI and modified CPMI as predictors of CVC risk in CCHD patients was assessed.